Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

124,423 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Venetoclax enhances T cell-mediated antileukemic activity by increasing ROS production.
Lee JB, Khan DH, Hurren R, Xu M, Na Y, Kang H, Mirali S, Wang X, Gronda M, Jitkova Y, MacLean N, Arruda A, Alaniz Z, Konopleva MY, Andreeff M, Minden MD, Zhang L, Schimmer AD. Lee JB, et al. Among authors: zhang l. Blood. 2021 Jul 22;138(3):234-245. doi: 10.1182/blood.2020009081. Blood. 2021. PMID: 34292323 Free PMC article.
Class II transactivator knockdown limits major histocompatibility complex II expression, diminishes immune rejection, and improves survival of allogeneic bone marrow stem cells in the infarcted heart.
Huang XP, Ludke A, Dhingra S, Guo J, Sun Z, Zhang L, Weisel RD, Li RK. Huang XP, et al. Among authors: zhang l. FASEB J. 2016 Sep;30(9):3069-82. doi: 10.1096/fj.201600331R. Epub 2016 May 24. FASEB J. 2016. PMID: 27221978
Decreasing CIITA expression in allogeneic MSCs abolished MHC II induction during myogenic differentiation and prevented immunorejection of these cells from the infarcted myocardium, which enhanced beneficial functional effects of MSC implantation on myocardial repair.-Huang, X.-P …
Decreasing CIITA expression in allogeneic MSCs abolished MHC II induction during myogenic differentiation and prevented immunorejection of t …
In vivo CRISPR screens reveal Serpinb9 and Adam2 as regulators of immune therapy response in lung cancer.
Dervovic D, Malik AA, Chen ELY, Narimatsu M, Adler N, Afiuni-Zadeh S, Krenbek D, Martinez S, Tsai R, Boucher J, Berman JM, Teng K, Ayyaz A, Lü Y, Mbamalu G, Loganathan SK, Lee J, Zhang L, Guidos C, Wrana J, Valipour A, Roux PP, Reimand J, Jackson HW, Schramek D. Dervovic D, et al. Among authors: zhang l. Nat Commun. 2023 May 31;14(1):3150. doi: 10.1038/s41467-023-38841-7. Nat Commun. 2023. PMID: 37258521 Free PMC article.
Author Correction: In vivo CRISPR screens reveal Serpinb9 and Adam2 as regulators of immune therapy response in lung cancer.
Dervovic D, Malik AA, Chen ELY, Narimatsu M, Adler N, Afiuni-Zadeh S, Krenbek D, Martinez S, Tsai R, Boucher J, Berman JM, Teng K, Ayyaz A, Lü Y, Mbamalu G, Loganathan SK, Lee J, Zhang L, Guidos C, Wrana J, Valipour A, Roux PP, Reimand J, Jackson HW, Schramek D. Dervovic D, et al. Among authors: zhang l. Nat Commun. 2023 Sep 5;14(1):5404. doi: 10.1038/s41467-023-41255-0. Nat Commun. 2023. PMID: 37670013 Free PMC article. No abstract available.
124,423 results
You have reached the last available page of results. Please see the User Guide for more information.